NEXANS ● The stock, which is currently worth 2019 to 0.44 times its sales, is clearly overvalued in comparison with peers.
● Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
● For the last week, the earnings per share forecast has been revised upwards. According to recent estimates, analysts give a positive overview of the stock
● Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
● Within the weekly time frame the stock shows a bullish technical configuration above the support level at 27.97 EUR
Weaknesses
● Stock prices approach a strong long-term resistance in weekly data at EUR 36.98.
● With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
● Low profitability weakens the company.
● Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
● Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
● The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
● For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
● For the past year, analysts have significantly revised downwards their profit estimates.
